Supporting Information

Selective recognition of *c-MYC* Pu22 G-quadruplex by a fluorescent probe

Qianqian Zhai ^{1,2}[†], Chao Gao ^{3,†}, Jieqin Ding ^{2,†}, Yashu Zhang ³, Barira Islam ⁴, Wenxian Lan ⁵, Haitao Hou ², Hua Deng ², Jun Li ², Zhe Hu ¹, Hany I. Mohamed ^{2,6}, Shengzhen Xu ², Chunyang Cao ⁵, Shozeb M. Haider ⁴ and Dengguo Wei ^{1,2}*

¹ State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, PR China

² College of Science, Huazhong Agricultural University, Wuhan 430070, China.

³ College of Plant Science and Technology, Huazhong Agricultural University, Wuhan 430070, PR China

⁴ UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, U.K.

⁵ State Key Laboratory of Bioorganic and Natural Products Chemistry and Collaborative Innovation Center of Chemistry for Life Sciences, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 345 Lingling Road, Shanghai, 200032, China

⁶ Chemistry Department, Faculty of Science, Benha University, Benha 13518, Egypt

Name	Type/origin	Structure	Sequence(5'→3')		
DNA G-quadruplex forming oligonucleotide sequences					
Bom17	G4-Bombyx telomere	Antiparallel	GGTTAGGTTAGGTTAGG		
Asc20	G4-Ascaris telomere	Antiparallel	GGCTTAGGCTTAGGCTTAGG		
CT4	G4/Mixed quartets	Antiparallel	GGGCTTTTGGGC		
TBA	G4-Aptamer	Antiparallel	GGTTGGTGTGGTTGG		
21CTA	G4-Human telomere	Antiparallel	GGGCTAGGGCTAGGGCTAGGG		
<i>c-MYC</i> Pu22	G4-Promoter	Parallel	TGAGGGTGGG <mark>T</mark> AGGGTGGG <mark>T</mark> AA		
<i>c-KIT</i> 1	G4-Promoter	Parallel	AGGGAGGGCGCTGGGAGGAGGG		
c-KIT 2	G4-Promoter	Parallel	GGGCGGGCGCGAGGGAGGGG		
Kras	G4-Promoter	Parallel	GGGCGGTGTGGGAAGAGGGAAGAGGGG		
VEGF	G4-Promoter	Parallel	CGGGGCGGGCCTTGGGCGGGGT		
AKT1	G4-Promoter	Parallel	GGGCGGGCGGCTCCGGGCGCGGG		
TTA	G4-Human DNA	Mixed	GGGTTAGGGTTAGGGTTAGGG		
TTA 45	G4-Human DNA	Mixed	GGGTTAGGGTTAGGGTTAGGGTTAGGG		
Plas24	G4-Plasmodium	Mixed	GGGTTCAGGGTTCAGGGTTCAGGG		
DNA Non-G-quadruplex forming oligonucleotide sequences					
CGG12	Trinucleotide	Trinucleotide	CGGCGGCGGCGGCGGCGGCGGCGGCG		
19AT			ACGTCGATTATAGACGAGC		
19AT-	Duplex	Duplex	GCTCGTCTATAATCGACGT		
dT30	Single strand	Single strand	TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT		
			(a) ТТТТТТТТТТТТТТТТТТТТТТТ		
Triplex	Triplex	Triplex	(b) AAAAAAAAAAAAAAAAAAAAAAAA		
			(с) ТТТТТТТТТТТТТТТТТТТТТ		
Wild-type G-quadruplex forming sequences in the promoter region <i>of c-MYC</i>					
<i>c-MYC</i> Pu18	G4-Promoter	er Parallel AGGGTGGGGGGGGGGGG			
<i>c-MYC</i> Pu24	G4-Promoter	Parallel	TGAGGGTGGGGAGGGTGGGGAAGG		
<i>c-MYC</i> Pu27	G4-Promoter	Parallel	TGGGGAGGGTGGGGAGGGTGGGGAAGG		
RNA G-quadruplex forming oligonucleotide sequences					
ADAM10	G4-5'-UTR	Parallel	GGGGGACGGGUAGGGGGGGGGGGGGGGGG		
ERSI	G4-5'-UTR	Parallel	GGGUAGGGGCAAAGGGGCUGGGG		
TRF2	G4-5'-UTR	Parallel	CGGGAGGGCGGGGGGGGGGC		
ZIC1	G4-5'-UTR	Parallel	GGGUGGGGGGGGGGGGGGGGGGGGGGGGG		
BCL-2	G4-5'-UTR	Parallel	AGGGGGCCGUGGGGUGGGAGCUGGGG		
VEGF	G4-5'-UTR	Parallel	GGAGGAGGGGGGGGGGGGGGG		
Tel22	G4-TERRA	Antiparallel	AGGGUUAGGGUUAGGGUUAGGG		
KRAS	G4-5'-UTR	Parallel	UGGCGGCGGCGAAGGU		

Table S1. DNA and RNA sequences used in	n the fluorescence i	intensity measurement
--	----------------------	-----------------------

Compounds	1	2	3	4	5(9CI)	6	7	8	9
E _{ex} /nm	308	378	298	305	405	307	379	366	277
E _{em} /nm	468	522	431	471	472	484	492	422	417
Compounds	10	11	12	13	14	15	16	17	18
E _{ex} /nm	356	334	365	310	348	310	308	305	361
E _{em} /nm	438	439	438	450	440	460	440	460	444
Compounds	19	20	21	22	23	24	25		
E _{ex} /nm	329	303	357	345	355	349	305		
E _{em} /nm	442	419	473	415	443	452	431		

Table S2. Excitation wavelength and emission wavelength of compounds 1-25

Name	Sequence(5'-3')		
<i>c-MYC</i> Pu22-MFP	TGAGGGTGGGTAGGGTGGGTAAAAAAAAAAA		
	GTAAAAAAAATGCCTGCGAGA		
TTA2-MFP	GGGTTAGGGTTAGGGTTAGGGAAAAAAGGGGTTAGGGTTAGGGTTAG		
	GGAAAAAATGCCTGCGAGA		
AS1411-M	GGTGGTGGTGGTTGTGGTGGTGGAAAAAA		

Table S3. Sequences of the oligonucleotides used in imaging AS1411

Scheme S1. Synthesis route of 9CI (compound 5) and compound 6.

Figure S1. Structures of compounds 10-25 and their fluorescent response.

Figure S2 Fluorescence responses of 9Cl (0.5 μ M) in the presence of various RNA G-quadruplex. The concentration of RNA G-quadruplex is 0.5 μ M. The samples were prepared in the buffer containing 10mM K₂HPO₄/KH₂PO₄ with 100mM KCl at pH 7.0

Figure S3. Predicted binding conformations of compound 1 (A) and 2 (B) at the 3' end cleft of *c-MYC* Pu22 G-quadruplex structure. Fluorophores in these two compounds are colored in purple.

Figure S4. A) ¹H NMR spectrum of 9Cl (compound 5); B) ¹³C NMR spectrum of 9Cl; C) HRMS of 9Cl.

Figure S5. A) ¹H NMR spectrum of Compound 6; B) ¹³C NMR spectrum of Compound 6; C) HRMS of Compound 6.

Figure S6. (A) Absorption spectra of 5 μ M 9CI in the buffer (10 mM K₂HPO₄/KH₂PO₄, pH 7.0, 100 mM KCl), (B) absorption spectra of 0.5 μ M 9CI in the presence of 0.5 μ M *c-MYC* Pu22 DNA oligonucleotide, (C) fluorescence spectra of 9CI (0.5 μ M) in the absence and the presence of *c-MYC* Pu22 DNA oligonucleotide (3 eq. to 9CI) with the excitation wavelength at 405 nm.

Figure S7. Linear fit equations for calculating the limits of detection (LOD) values of compound 9CI (0.5 μ M) for *c-MYC* Pu22 G-quadruplex forming DNA oligonucleotide in buffer (10 mM K₂HPO₄/KH₂PO₄, pH 7.0, 100 mM KCl) at room temperature ($\lambda_{ex} = 405$ nm, $\lambda_{em} = 472$ nm).

Figure S8. Cytotoxicity effect of 9CI on A549 cells.

Figure S9. Fluorescence response of 0.5 µM 9CI and mixture (0.5 µM c-MYC Pu22 and 0.5

 μ M 9CI) in buffer and cell lysate at Ex = 405 nm. Buffer: 10 mM K₂HPO₄/KH₂PO₄, 100 mM KCl pH 7.0; cell lysate: 30000 cells/mL of A549 in solution (10 mM K₂HPO₄/KH₂PO₄, 100 mM KCl pH 7.0).

Figure S10. Fluorescence images of A549 cells transfected with 40 pmol labelled TTA G-quadruplex forming oligonucleotide using lipofectamine 2000, and then incubated with 5µM 9Cl for 2 hours. (A) Fluorescence signal collected between 655-755 nm at $\lambda_{ex} = 635$ nm, (B) fluorescence signal collected between 425-470nm at $\lambda_{ex} = 405$ nm, (C) fluorescence signal collected between 500-545nm at $\lambda_{ex} = 405$ nm, (D) merged image of (B) and (C). (E) merged images of (A), (B), (C) and bright field. Scale bar, 20 µm.

Figure S11. Fluorescence images of A549 cells transfected with 40 pmol labelled *c-KIT*1 G-quadruplex forming oligonucleotide using lipofectamine 2000, and then incubated with 5 μ M 9Cl for 2 hours. (A) Fluorescence signal collected between 655-755 nm at $\lambda_{ex} = 635$ nm, (B) fluorescence signal collected between 425-470nm at $\lambda_{ex} = 405$ nm, (C) fluorescence signal collected between 500-545 nm at $\lambda_{ex} = 405$ nm, (D) merged image of (B) and (C), (E) merged images of (A), (B), (C) and bright field. Scale bar, 20 μ m.

Figure S12. Fluorescence images of A549 cells transfected with 40 pmol *c-MYC* Pu22 G-quadruplex forming oligonucleotide labelled with Cy3 using lipofectamine 2000, and then incubated with 5 μ M 9Cl for 2 hours. (A) Fluorescence signals at $\lambda_{ex} = 405$ nm, $\lambda_{em} = 500-545$ nm; (B) fluorescence signals at $\lambda_{ex} = 405$ nm, $\lambda_{em} = 570-625$ nm (Cy3); (C) merged image of (A),(B) and bright field; (D) image of 9CI prior to photobleaching of the acceptor Cy3 (insert), (E) the fluorescence enhancement of 9CI after Cy3 was photobleached (insert), (F) FRET efficiency measured with the donor quenching approach, and the color bar represents the FRET efficiency. Scale bar, 10 µm.

Figure S13. Fluorescence spectra of solution at $\lambda_{ex} = 405 \text{ nm.1}$) 1 μ M 9CI (black line); 2) 1 μ M 9CI and 0.5 μ M *c-MYC* Pu22 DNA (red line); 3) 1 μ M 9CI, 0.5 μ M *c-MYC* Pu22-MFP

DNA and 0.5 μ M SL1-M (blue line).

Figure S14. Confocal microscopy images of the treated A549 cells and HEK293T cells at 405 nm excitation. Cells was incubated with AS1411-M for 30 min at room temperature, and washed by 1 mL DPBS twice. Then, the cells were incubated with 500 nM MFP (*c-MYC* Pu22-MFP/ TTA-MFP) and 5μ M 9CI for 10 min. Fluorescence signals were collected after the cells were washed with DPBS three times again. (A) Fluorescence signals collected at 425-470 nm emission channel, (B) fluorescence signals collected at 500-545 nm emission channel, (C) merged image of (A) and (B) and bright field. Scale bar, 10 µm.

Figure S15. Job plot analysis for the binding stoichiometry of 9CI to *c-MYC* Pu22 G-quadruplex in 10 mM KH₂PO₄/K₂HPO₄ buffer (pH 7.0) with 100 mM KCl at room temperature. The sum of the concentration of 9CI and the concentration of *c-MYC* Pu22 G-quadruplex-forming oligonucleotide was fixed at 2 μ M. The fluorescence intensity was plotted against molar ratio of [9CI]/([9CI] + [DNA]). The excitation wavelength was set at 405 nm, and the emission was collected at 472 nm. The intersection point is near 0.5, where 9CI exhibits binding of 1:1 stoichiometry to *c-MYC* Pu22 G-quadruplex.

Figure S16. ITC binding isotherm of 20 μ M 9CI interacting with 150 μ M *c-MYC* Pu22 G-quadruplex DNA. This experiment was performed in buffer with 100 mM KCl, 10 mM KH₂PO₄/K₂HPO₄ (pH 7.0) at 25 °C.

Figure S17. Linear relationship of fluorometric titration. Benesi-Hildebrand plot of $1/(F-F_0)$ versus 1/[DNA]. The Ka value was calculated as 8.33 x 10^5 M⁻¹ for the binding between *c-MYC* Pu22 G-quadruplex and 9CI.

Figure S18. CD spectra of 10 μ M G-quadruplex-forming oligonucleotides *c-MYC* Pu22, *c-KIT1*, TTA, TBA and CT4 in 10 mM KH₂PO₄/K₂HPO₄ buffer, 100 mM KCl, pH 7.0, with/without 20 μ M 9CI at room temperature.

Figure S19. CD spectra of 10 μ M *c-MYC* Pu22 DNA G-quadruplex oligonucleotide and the mutated oligonucleotides: *c-MYC* Pu22 G2>C2, *c-MYC* Pu22 T11>A11, *c-MYC* Pu22 T20>A20, *c-MYC* Pu22 A22>T22, *c-MYC* Pu22 A3>T3, *c-MYC* Pu22 G10>T10 in 10 mM KH₂PO₄/K₂HPO₄ buffer, 100 mM KCl, pH 7.0, with/without 20 μ M 9CI at room temperature.

Figure S20. Binding model of 9CI in the 3' end cleft of *c-MYC* Pu22 G-quadruplex as predicted by Autodock 4.0. G-quadruplex is in yellow stick, and 9CI is in green. Figure B was obtained by rotating 90° from Figure A.

Figure S21. (A) RMSD of nucleic acid backbone in *c-MYC* Pu22 G-quadruplex structure over the course of the molecular dynamic simulation between 9CI and *c-MYC* Pu22 G-quadruplex. The inset structures highlight the conformation of binding at 100ns, 300ns, 500ns, 700ns and 1000ns. (B) Distance between C1' atoms of G19 and T20; (C) distance between C1' atoms of T20 and A22. (D) Conformational flexibility of the T20-A21-A22 loop observed over the course of the simulation. The figure illustrates 20 structures extracted every 50 ns. The conformation of the ligand (yellow) and the rest of the G-quadruplex is a snapshot taken at 1000 ns.

Figure S22. Binding modes of 9CI in the 3' end cleft of *c-MYC* Pu22 G-quadruplex explored by molecular dynamics simulation. Three figures are in different orientation.

Figure S23. Fluorescence intensity variance of 9CI (1 μ M) in buffer (10mM K₂HPO₄/KH₂PO₄ with 100 mM KCl at pH 7.0) with glycerol at different concentrations.

Figure S24. 1D ¹H NMR spectra of *c-MYC* Pu22 G-quadruplex DNA mixing with d6-DMSO at different ratios (V/V).

Scheme S1. Synthesis route of 9Cl (compound 5) and compound 6



9CI (Compound 5): I= anthracene-9-carbaldehyde

Compound 6: I= anthracene-2-carbaldehyde



Figure S1. Structures of compounds 10-25 and their fluorescent response to eighteen DNA oligonucleotides^a.

^a The excitation and emission wavelengths of these compounds are listed in Table S2.

Figure S2. Fluorescence responses of 9Cl (0.5 μ M) in the presence of various RNA G-quadruplex forming oligonucleotides (Table S1). The concentration of RNA G-quadruplex is 0.5 μ M. The samples were prepared in the buffer containing 10 mM K₂HPO₄/KH₂PO₄ with 100 mM KCl at pH 7.0.



Figure S3. Predicted binding conformations of compound 1 (A) and 2 (B) at the 3' end cleft of *c-MYC* Pu22 G-quadruplex structure. Fluorophores in these two compounds are colored in purple.



Figure S4. A) ¹H NMR spectrum of 9Cl (compound 5); B) ¹³C NMR spectrum of 9Cl; C) HRMS of 9Cl.



Figure S5. A) ¹H NMR spectrum of Compound 6; B) ¹³C NMR spectrum of Compound 6; C) HRMS of Compound 6.



Figure S6. (A) Absorption spectra of 5 μ M 9CI in the buffer (10 mM K₂HPO₄/KH₂PO₄, pH 7.0, 100 mM KCl), (B) absorption spectra of 0.5 μ M 9CI in the presence of 0.5 μ M *c-MYC* Pu22 DNA oligonucleotide, (C) fluorescence spectra of 9CI (0.5 μ M) in the absence and the presence of *c-MYC* Pu22 DNA oligonucleotide (3 eq. to 9CI) with the excitation wavelength at 405 nm.



Figure S7. Linear fit equations for calculating the limits of detection (LOD) values of compound 9CI (0.5 μ M) for *c-MYC* Pu22 G-quadruplex forming DNA oligonucleotide in buffer (10 mM K₂HPO₄/KH₂PO₄, pH 7.0, 100 mM KCl) at room temperature ($\lambda_{ex} = 405$ nm, $\lambda_{em} = 472$ nm).



Figure S8. Cytotoxicity effect of 9CI on A549 cells.



Figure S9. Fluorescence response of 0.5 μ M 9CI and mixture (0.5 μ M *c-MYC* Pu22 and 0.5 μ M 9CI) in buffer and cell lysate at Ex = 405 nm. Buffer: 10 mM K₂HPO₄/KH₂PO₄, 100 mM KCl pH 7.0; cell lysate: 30000 cells/mL of A549 in solution (10 mM K₂HPO₄/KH₂PO₄, 100 mM KCl pH 7.0).



Figure S10. Fluorescence images of A549 cells transfected with 40 pmol labelled TTA G-quadruplex forming oligonucleotide using lipofectamine 2000, and then incubated with 5 μ M 9Cl for 2 hours. (A) Fluorescence signal collected between 655-755 nm at $\lambda_{ex} = 635$ nm, (B) fluorescence signal collected between 425-470nm at $\lambda_{ex} = 405$ nm, (C) fluorescence signal collected between 500-545nm at $\lambda_{ex} = 405$ nm, (D) merged image of (B) and (C), (E) merged images of (A), (B), (C) and bright field. Scale bar, 20 μ m.



Figure S11. Fluorescence images of A549 cells transfected with 40 pmol labelled *c-KIT*1 G-quadruplex forming oligonucleotide using lipofectamine 2000, and then incubated with 5 μ M 9Cl for 2 hours. (A) Fluorescence signal collected between 655-755 nm at $\lambda_{ex} = 635$ nm, (B) fluorescence signal collected between 425-470nm at $\lambda_{ex} = 405$ nm, (C) fluorescence signal collected between 500-545nm at $\lambda_{ex} = 405$ nm, (D) merged image of (B) and (C), (E) merged images of (A), (B), (C) and bright field. Scale bar, 20 μ m.



Figure S12 Fluorescence images of A549 cells transfected with 40 pmol *c-MYC* Pu22 G-quadruplex forming oligonucleotide labelled with Cy3 using lipofectamine 2000, and then incubated with 5 μ M 9Cl for 2 hours. (A) Fluorescence signals at $\lambda_{ex} = 405$ nm, $\lambda_{em} = 500-545$ nm; (B) fluorescence signals at $\lambda_{ex} = 405$ nm, $\lambda_{em} = 570-625$ nm (Cy3); (C) merged image of (A),(B) and bright field; (D) image of 9CI prior to photobleaching of the acceptor Cy3 (insert), (E) the fluorescence enhancement of 9CI after Cy3 was photobleached (insert), (F) FRET efficiency measured with the donor quenching approach, and the color bar represents the FRET efficiency. Scale bar, 10 μ m.



FRET between 9CI and Cy3 could provide direct evidence for the recognition between them. According to the emission spectrum of complex and the absorption spectrum of Cy3, FRET could happen between 9CI and Cy3. After the Cy3 labeled *c-MYC* Pu22 and 9CI were transfected to A549 cells, at the excitation wavelength of 9CI, the fluorescence signals collected between 500 nm and 545 nm (Figure S12A) showed the location of 9CI, and the fluorescence signals collected between 570 nm and 625nm suggested the FRET happen between 9CI and Cy3 (Figure S12B).

A donor dequenching approach was employed to validate FRET between 9CI and Cy3. Fluorescence intensity of 9CI was measured before and after the photobleaching of the Cy3 acceptor. The FRET efficiency was calculated as E= (DQ-Q/DQ), where DQ is the fluorescence intensities at the dequenched state, and the Q is the fluorescence intensities at the quenched state. Compared with the fluorescence intensity of 9CI at the quenched state, the increased fluorescence intensity of 9CI at the dequenched state further proved the existence of FRET between 9CI and Cy3 (Figure S12 D-F). Prebleach and postbleach images were taken serially with lower laser intensity.

Figure S13. Fluorescence spectra of solution at $\lambda_{ex} = 405 \text{ nm.1}$) 1 µM 9CI (black line); 2) 1 µM 9CI and 0.5 µM *c-MYC* Pu22 DNA (red line); 3) 1 µM 9CI, 0.5 µM *c-MYC* Pu22-MFP DNA and 0.5 µM SL1-M (blue line).



Figure S14. Confocal microscopy images of the treated A549 cells and HEK293T cells at 405 nm excitation for locating AS1411. Cells was incubated with AS1411-M for 30 min at room temperature, and washed by 1 mL DPBS twice. Then, the cells were incubated with 500 nM MFP (*c-MYC* Pu22-MFP/TTA-MFP) and 5 μ M 9CI for 10 min. Fluorescence signals were collected after the cells were washed with DPBS three times again. (A) Fluorescence signals collected at 425-470 nm emission channel, (B) fluorescence signals collected at 500-545 nm emission channel, (C) merged image of (A) and (B) and bright field. Scale bar, 10 µm.



Figure S15. Job plot analysis for the binding stoichiometry of 9CI to *c-MYC* Pu22 G-quadruplex in 10 mM KH₂PO₄/K₂HPO₄ buffer (pH 7.0) with 100 mM KCl at room temperature. The sum of the concentration of 9CI and the concentration of *c-MYC* Pu22 G-quadruplex-forming oligonucleotide was fixed at 2 μ M. The fluorescence intensity was plotted against molar ratio of [9CI]/([9CI] + [DNA]). The excitation wavelength was set at 405 nm, and the emission was collected at 472 nm. The intersection point is near 0.5, where 9CI exhibits binding of 1:1 stoichiometry to *c-MYC* Pu22 G-quadruplex.



Figure S16. ITC binding isotherm of 20 μ M 9CI interacting with 150 μ M *c-MYC* Pu22 G-quadruplex DNA. This experiment was performed in buffer with 100 mM KCl, 10 mM KH₂PO₄/K₂HPO₄ (pH 7.0) at 25 °C.



Figure S17. Linear relationship of fluorometric titration. Benesi-Hildebrand plot of $1/(F-F_0)$ versus 1/[DNA]. The Ka value was calculated as 8.33 x 10^5 M⁻¹ for the binding between *c-MYC* Pu22 G-quadruplex and 9CI.



Figure S18. CD spectra of 10 μ M G-quadruplex-forming oligonucleotides *c-MYC* Pu22, *c-KIT1*, TTA, TBA and CT4 in 10 mM KH₂PO₄/K₂HPO₄ buffer, 100 mM KCl, pH 7.0, with/without 20 μ M 9CI at room temperature.



Figure S19. CD spectra of 10 μ M *c-MYC* Pu22 DNA G-quadruplex oligonucleotide and the mutated oligonucleotides: *c-MYC* Pu22 G2>C2, *c-MYC* Pu22 T11>A11, *c-MYC* Pu22 T20>A20, *c-MYC* Pu22 A22>T22, *c-MYC* Pu22 A3>T3, *c-MYC* Pu22 G10>T10 in 10 mM KH₂PO₄/K₂HPO₄ buffer, 100 mM KCl, pH 7.0, with/without 20 μ M 9CI at room temperature.



Figure S20. Binding model of 9CI in the 3' end cleft of *c-MYC* Pu22 G-quadruplex as predicted by Autodock 4.0. G-quadruplex is in yellow stick, and 9CI is in green. Figure S20B was obtained by rotating 90° from Figure S20A.



Figure S21. (A) RMSD of nucleic acid backbone in *c-MYC* Pu22 G-quadruplex structure over the course of the molecular dynamic simulation between 9CI and *c-MYC* Pu22 G-quadruplex. The inset structures highlight the conformation of binding at 100ns, 300ns, 500ns, 700ns and 1000ns. (B) Distance between C1' atoms of G19 and T20; (C) distance between C1' atoms of T20 and A22. (D) Conformational flexibility of the T20-A21-A22 loop observed over the course of the simulation. The figure illustrates 20 structures extracted every 50 ns. The conformation of the ligand (yellow) and the rest of the G-quadruplex is a snapshot taken at 1000 ns.



Figure S22. Binding modes of 9CI in the 3' end cleft of *c-MYC* Pu22 G-quadruplex explored by molecular dynamics simulation. Three figures are in different orientation.



Figure S23 Fluorescence intensity variance of 9CI (1 μ M) in buffer (10mM K₂HPO₄/KH₂PO₄ with 100 mM KCl at pH 7.0) with glycerol at different concentrations.



Figure S24 1D ¹H NMR spectra of *c-MYC* Pu22 G-quadruplex DNA mixing with d6-DMSO at different ratios (V/V).

